Cargando…

Effect of Food on the Pharmacokinetics of Quizartinib

Quizartinib is an oral, highly potent, and selective type II FMS‐like tyrosine kinase 3 inhibitor in development for acute myeloid leukemia. This parallel‐group study evaluated potential food effects on quizartinib absorption in healthy subjects who received a single 30‐mg dose after overnight fasti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jianke, Holmes, Melissa, Kankam, Martin, Trone, Denise, Mendell, Jeanne, Gammon, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027461/ https://www.ncbi.nlm.nih.gov/pubmed/31916418 http://dx.doi.org/10.1002/cpdd.770

Ejemplares similares

Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
por: Li, Jianke, et al.
Publicado: (2019)

A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
por: Li, Jianke, et al.
Publicado: (2019)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
por: Papadopoulos, Kyriakos P., et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
por: Ouchida, Amanda Tomie, et al.
Publicado: (2018)

Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
por: Zorn, Julie A., et al.
Publicado: (2015)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
por: Schaab, C, et al.
Publicado: (2014)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
por: Fletcher, Luke, et al.
Publicado: (2020)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2021)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

THU467 Pharmacokinetics And Pharmacodynamics Of Garetosmab In Patients With Fibrodysplasia Ossificans Progressiva
por: Wang, Yuhuan, et al.
Publicado: (2023)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

The effect of food on the pharmacokinetics of oral fluralaner in dogs
por: Walther, Feli M, et al.
Publicado: (2014)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
por: Kankam, Martin K., et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects
por: Garey, Kevin W, et al.
Publicado: (2020)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers
por: Osborn, Megan, et al.
Publicado: (2019)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies
por: Sun, Ming-Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oe5udqefaf70g6t5st1taoea03